C4 Therapeutics Inc (NAS:CCCC)
$ 6.09 -0.36 (-5.58%) Market Cap: 429.89 Mil Enterprise Value: 266.75 Mil PE Ratio: 0 PB Ratio: 1.77 GF Score: 58/100

C4 Therapeutics Inc at Credit Suisse Healthcare Conference Transcript

Nov 08, 2022 / 10:00PM GMT
Release Date Price: $9.08 (+2.48%)
Jin Law;dit Suisse AG
CrÃ;Research Division - Senior Analyst

© -

And why don't we get going with the Q&A? Well, first of all, welcome.

Andrew J. Hirsch
C4 Therapeutics, Inc. - CEO, President & Director

Great. Thanks for having us.

Questions & Answers

Jin Law;dit Suisse AG
CrÃ;Research Division - Senior Analyst

© -

And a pleasure to be hosting you. So why don't we talk about C4's development strategy a little bit? You guys tend to go into indications that have proven targets, but these indications are very crowded. So when I look at it, is basically derisked from a science or biology perspective, but very high bar for success commercially. Is that a fair statement?

Andrew J. Hirsch
C4 Therapeutics, Inc. - CEO, President & Director

Well, I think what you're seeing is the strategy play out the company started with, which is a very classic strategy for a new platform company where you don't want to add

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot